Can a common parasite drug boost cancer immunotherapy?
NCT ID NCT07487805
First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside their standard treatment. Researchers will measure changes in immune cells and watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivermectin
- What this could lead to
- If it works, this could show that adding ivermectin to standard immunotherapy improves the immune system's ability to fight cancer.
- What could go wrong
- This is a small, early-phase trial with only 80 participants. Ivermectin may cause side effects or interact with other drugs, and it might not boost immunity as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Zinc-Based compound fight cancer?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?
- New imaging agent aims to light up hidden tumors
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
- New scan could reveal hidden cancer cells